Regulatory T cells in kidney diseases: context-dependent functions and therapeutic potential.
文献摘要
Kidney diseases, including acute kidney injury (AKI), chronic kidney disease (CKD), IgA nephropathy (IgAN), lupus nephritis (LN), and kidney transplantation, share features of immune dysregulation, persistent inflammation, and progressive fibrosis. Regulatory T cells (Tregs) are central to immune tolerance in the kidney, yet their function is not uniform: it is shaped by developmental origin, disease etiology, disease stage and the metabolic and inflammatory tone of the renal microenvironment. Single-cell and spatially resolved profiling has revealed tissue-resident, activated, dysfunctional, and senescent Treg states in the injured kidney, and has begun to define the renal Treg niche. Building on this evidence, we propose an etiology- and stage-stratified framework in which Tregs protect against acute injury, promote repair, or, under specific conditions, contribute to fibrotic remodeling. This framework rationalizes therapeutic targeting: cytokine and small-molecule Treg expansion (notably low-dose IL-2), Treg-compatible optimization of conventional immunosuppression, adoptive polyclonal and antigen-specific CAR/TCR-Treg therapies, and metabolic or tissue-targeted engineering should be matched to disease etiology and stage. Integrating spatial multi-omics, lineage-stabilizing strategies, and standardized manufacturing and monitoring will be essential to translate Treg-based therapies into precision treatments for kidney diseases.